🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thanks to @MedPageToday and Kristina Fiore for covering our recent work on HIV PrEP in Health with this great summary! medpagetoday.com/special-report… Program On Regulation, Therapeutics, And Law UChicago Pritzker School of Medicine

Are myocardial bridges more common than we’ve previously thought? Proud to have our abstract published in JACC jacc.org/doi/10.1016/S0…

In their paper, Frazer Tessema +coauthors determine that government funding for the discovery and development of the first HIV PrEP medication included $143 million in direct funding from NIH and an additional $314 million in "potentially related awards." bit.ly/45uOhQ8

Thanks for the shoutout Samer! If we are going to talk about access to CAR T, we must talk about ALL elements of cost: - manufacturing - price charged by manufacturers - hospital charges Thanks to Amar Kelkar, MD, MPH, FACP David Russler-Germain, MD/PhD Adam Raymakers Frazer Tessema William Feldman Aaron Kesselheim

Lots of great new work from Program On Regulation, Therapeutics, And Law at AcademyHealth #ARM23 this year! Come stop by!

We wrote about the relationship between #DrugShortages & niche markets (drugs with ≤3 manufacturers) in @HastingsLJ Today, many generic cancer drugs are precariously located in this "Bermuda triangle" - we offer several reforms in #GenericButExpensive: papers.ssrn.com/sol3/papers.cf…

Delighted to share our ASCO Education Book article: the High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions We review the factors leading to the extremely high cost of CAR T-cells & propose potential solutions 🧵👇 ascopubs.org/doi/abs/10.120… #ASCO23

Certainly need to watch this situation closely Is accelerated approval the right path for gene therapy? Seems we will find out...! Frazer Tessema Michael Makris Joshua Budhu Program On Regulation, Therapeutics, And Law

Happy to collaborate with Dhruv Kazi and Rishi Wadhera, MD MPP from BIDMC Smith Center on this new viewpoint about the potential benefits of the IRA for patient affordability of medications.

🚨 Very important news. “Today, the US Food & Drug Administration approved 2 milestone treatments, representing the first cell-based gene therapies for the treatment of #SickleCellDisease.” Now to make sure it gets to those who need it. #Pharmacoequity fda.gov/news-events/pr…

Of relevance, and article Frazer Tessema wrote in The Journal of Law, Medicine & Ethics: "High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine" cambridge.org/core/journals/…

🚨 New Study in JGIM Journal of General Internal Medicine - We evaluated the availability & cost of common & expensive generics at 5 direct to consumer pharmacies We found that 20% of expensive generics were NOT available any DTC pharmacy while most common generics were 🧵 Read -- link.springer.com/article/10.100…

New invited commentary published in JGIM Journal of General Internal Medicine! I discuss direct-to-consumer pharmacies and whether they can improve access to medicines for patients, as well as respond to a recent study published by Hussain Lalani, MD, MPH, MSc Frazer Tessema Aaron Kesselheim Ben Rome lnkd.in/gkXzCDYW

New JAMA Viewpoint article with Eddie Cliff and Program On Regulation, Therapeutics, And Law on incorporating health equity considerations into the pricing of Sickle Cell Disease gene therapies using CRISPR-Cas9 and Lentiviral Technology. Full text here: jamanetwork.com/journals/jama/…

Just out JAMA: Frazer Tessema & I discuss the challenge & some potential approaches to the extremely high prices of gene therapies for sickle cell disease. An exciting scientific & medical advance - now urgently need to enable patient access jamanetwork.com/journals/jama/…

Thanks UChicago Pritzker School of Medicine Health Policy Interest Group for sponsoring "Physician Advocacy Post-Election: What’s Next?” Had blast on panel with Anna Volerman, MD Colleen Grogan @AnthonyDDouglas moderated by Frazer Tessema